FI4027973T3 - Lääkkeensaattoformulaatioita - Google Patents
LääkkeensaattoformulaatioitaInfo
- Publication number
- FI4027973T3 FI4027973T3 FIEP20772437.8T FI20772437T FI4027973T3 FI 4027973 T3 FI4027973 T3 FI 4027973T3 FI 20772437 T FI20772437 T FI 20772437T FI 4027973 T3 FI4027973 T3 FI 4027973T3
- Authority
- FI
- Finland
- Prior art keywords
- formulation
- pharmaceutical formulation
- risperidone
- use according
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900061P | 2019-09-13 | 2019-09-13 | |
| PCT/IB2020/058474 WO2021048817A1 (en) | 2019-09-13 | 2020-09-11 | Drug delivery formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4027973T3 true FI4027973T3 (fi) | 2026-01-14 |
Family
ID=72521677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20772437.8T FI4027973T3 (fi) | 2019-09-13 | 2020-09-11 | Lääkkeensaattoformulaatioita |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12383493B2 (OSRAM) |
| EP (2) | EP4027973B8 (OSRAM) |
| JP (2) | JP7661312B2 (OSRAM) |
| KR (1) | KR20220062372A (OSRAM) |
| CN (1) | CN114727946A (OSRAM) |
| AU (2) | AU2020346455B2 (OSRAM) |
| BR (1) | BR112022004535A2 (OSRAM) |
| CA (1) | CA3153793A1 (OSRAM) |
| DK (1) | DK4027973T3 (OSRAM) |
| ES (1) | ES3058225T3 (OSRAM) |
| FI (1) | FI4027973T3 (OSRAM) |
| HR (1) | HRP20251690T1 (OSRAM) |
| IL (1) | IL291283A (OSRAM) |
| LT (1) | LT4027973T (OSRAM) |
| MX (1) | MX2022003051A (OSRAM) |
| PL (1) | PL4027973T3 (OSRAM) |
| PT (1) | PT4027973T (OSRAM) |
| SI (1) | SI4027973T1 (OSRAM) |
| WO (1) | WO2021048817A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018652A2 (pt) * | 2021-03-17 | 2023-10-03 | Medincell S A | Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis |
| PE20252752A1 (es) * | 2023-01-10 | 2025-12-05 | Medincell Sa | Composiciones de olanzapina y metodos de uso |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1024790A4 (en) | 1997-08-08 | 2000-10-25 | Univ Utah Res Found | INJECTABLE BIODEGRADABLE BLOCK COPOLYMER GELS FOR USE IN DRUG ADMINISTRATION |
| CA2474968A1 (en) | 2002-01-31 | 2003-08-07 | Asahi Techno Glass Corporation | Cryopreservation medium for primate embryo stem cells and cryopreservation method |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| AU2009298637B2 (en) | 2008-09-30 | 2015-08-13 | Braeburn Pharmaceuticals, Inc. | Implantable device for the delivery of risperidone and methods of use thereof |
| CN101584652B (zh) * | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| MX347090B (es) * | 2010-12-29 | 2017-04-11 | Medincell | Composiciones de suministro de farmacos biodegradables. |
| EP2770983B1 (en) * | 2011-10-24 | 2017-04-19 | Braeburn Pharmaceuticals, Inc. | Implantable drug delivery compositions and methods of treatment thereof |
| JP6134788B2 (ja) * | 2012-06-27 | 2017-05-24 | メドインセルル | 疎水性組成物のための生分解性薬物送達 |
| EP2986278A1 (en) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| ES3015765T3 (en) | 2017-07-17 | 2025-05-07 | Medincell S A | Pharmaceutical composition |
-
2020
- 2020-09-11 ES ES20772437T patent/ES3058225T3/es active Active
- 2020-09-11 SI SI202030708T patent/SI4027973T1/sl unknown
- 2020-09-11 MX MX2022003051A patent/MX2022003051A/es unknown
- 2020-09-11 EP EP20772437.8A patent/EP4027973B8/en active Active
- 2020-09-11 FI FIEP20772437.8T patent/FI4027973T3/fi active
- 2020-09-11 LT LTEPPCT/IB2020/058474T patent/LT4027973T/lt unknown
- 2020-09-11 DK DK20772437.8T patent/DK4027973T3/da active
- 2020-09-11 BR BR112022004535A patent/BR112022004535A2/pt unknown
- 2020-09-11 PL PL20772437.8T patent/PL4027973T3/pl unknown
- 2020-09-11 WO PCT/IB2020/058474 patent/WO2021048817A1/en not_active Ceased
- 2020-09-11 EP EP25212808.7A patent/EP4706658A2/en active Pending
- 2020-09-11 JP JP2022516406A patent/JP7661312B2/ja active Active
- 2020-09-11 KR KR1020227012200A patent/KR20220062372A/ko active Pending
- 2020-09-11 AU AU2020346455A patent/AU2020346455B2/en active Active
- 2020-09-11 CN CN202080077874.0A patent/CN114727946A/zh active Pending
- 2020-09-11 US US17/642,410 patent/US12383493B2/en active Active
- 2020-09-11 HR HRP20251690TT patent/HRP20251690T1/hr unknown
- 2020-09-11 CA CA3153793A patent/CA3153793A1/en active Pending
- 2020-09-11 PT PT207724378T patent/PT4027973T/pt unknown
-
2022
- 2022-03-10 IL IL291283A patent/IL291283A/en unknown
-
2023
- 2023-12-20 US US18/391,243 patent/US12128132B2/en active Active
-
2025
- 2025-04-02 JP JP2025060885A patent/JP2025106353A/ja active Pending
- 2025-05-12 US US19/205,563 patent/US20250268817A1/en active Pending
- 2025-09-30 AU AU2025242078A patent/AU2025242078A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4027973B1 (en) | 2025-11-05 |
| IL291283A (en) | 2022-05-01 |
| US12383493B2 (en) | 2025-08-12 |
| EP4027973A1 (en) | 2022-07-20 |
| BR112022004535A2 (pt) | 2022-06-07 |
| ES3058225T3 (en) | 2026-03-09 |
| US20240156722A1 (en) | 2024-05-16 |
| LT4027973T (lt) | 2026-01-26 |
| US20250268817A1 (en) | 2025-08-28 |
| CA3153793A1 (en) | 2021-03-18 |
| US20220331240A1 (en) | 2022-10-20 |
| JP7661312B2 (ja) | 2025-04-14 |
| PL4027973T3 (pl) | 2026-03-09 |
| AU2025242078A1 (en) | 2025-10-23 |
| CN114727946A (zh) | 2022-07-08 |
| MX2022003051A (es) | 2022-06-14 |
| SI4027973T1 (sl) | 2026-02-27 |
| DK4027973T3 (da) | 2026-01-12 |
| PT4027973T (pt) | 2026-01-05 |
| JP2025106353A (ja) | 2025-07-15 |
| EP4706658A2 (en) | 2026-03-11 |
| AU2020346455A1 (en) | 2022-03-31 |
| AU2020346455B2 (en) | 2025-07-03 |
| HRP20251690T1 (hr) | 2026-02-13 |
| JP2022548616A (ja) | 2022-11-21 |
| EP4027973B8 (en) | 2025-12-17 |
| WO2021048817A1 (en) | 2021-03-18 |
| KR20220062372A (ko) | 2022-05-16 |
| US12128132B2 (en) | 2024-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2582395B1 (en) | Methods for the preparation of injectable depot compositions | |
| CN103491946B (zh) | 可生物降解的药物释放组合物 | |
| CN103002917B (zh) | 可注射长效抗精神病组合物 | |
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| KR102189442B1 (ko) | 소수성 조성물용 생분해성 약물 전달 | |
| CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
| US12016951B2 (en) | Edaravone pharmaceutical composition | |
| CA2468703A1 (en) | Controlled release polymeric compositions of bone growth promoting compounds | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| KR20160112012A (ko) | 질내 투여용 속용성 정제 조성물 | |
| MX2022000489A (es) | Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. | |
| US20220071988A1 (en) | Sustained release buprenorphine microspheres (srbm) and methods of use thereof | |
| JP2022548616A5 (OSRAM) | ||
| KR20210006426A (ko) | 안정한 약제학적 제제 | |
| WO2011112161A1 (en) | Extended release thiocolchicoside tablets | |
| JP2022548616A (ja) | 薬物送達製剤 | |
| US20240123021A1 (en) | Pharmaceutical compositions | |
| JP7402806B2 (ja) | ４０－ｏ－環状炭化水素エステル及び関連構造のための非経口製剤材料及び方法 | |
| JP2024511353A5 (OSRAM) | ||
| JPWO2015133580A1 (ja) | 注入可能なポリ乳酸類含有組成物 | |
| JP2003238391A (ja) | 局所投与型徐放性軟膏 | |
| HK1235301A1 (en) | Pharmaceutical compositions comprising lobeglitazone for oral administration |